Trial Profile

Pan-EU Real-World Experience With Imraldi

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 28 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adalimumab (Primary)
Indications Axial spondyloarthritis; Crohn's disease; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
Focus Therapeutic Use
Acronyms PROPER
Sponsors Biogen

Most Recent Events

14 Nov 2022 Results of 48-week analysis for the Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis cohorts presented at the ACR Convergence 2022.
04 Jun 2022 Results of an analysis of 48-Week from the rheumatology cohort presented at the 23rd Annual Congress of the European League Against Rheumatism
31 May 2022 According to a Samsung Bioepis media release, data from this trial will be presented at the Annual European Congress of Rheumatology (EULAR 2022).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com